Melanoma Great Debate: Targeted versus Complete Nodal Dissection following Neoadjuvant Therapy for Melanoma: Is it Time to Push Forward or Hold off on Continued De-escalation of Surgery?
Attending Memorial Sloan Kettering Cancer Center New York, New York, United States
Neoadjuvant immunotherapy has been increasingly adopted for the treatment of patients with clinically apparent stage 3 disease. As this becomes increasingly adopted, it is unclear if targeted lymph node removal, albeit potentially prognostic, is sufficient to manage the regional nodal basin. This debate will highlight the evidence for this approach and future directions in the field of neoadjuvant immunotherapy for the treatment of melanoma.
